EAJF Stock Chart & Stats
€0.02
€0.00(0.00%)
At close: 4:00 PM EST
€0.02
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€0.01 - €0.12
Previous CloseN/A
Volume0.00
Average Volume (3M)N/A
Market Cap
€2.68M
Enterprise Value-€114.83K
Total Cash (Recent Filing)€970.56K
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta-3.82
Next Earnings
Jun 09, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,320,301,000
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.49
Price to Sales (P/S)44.16
P/FCF Ratio-0.91
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Very Low LeverageMinimal debt materially reduces interest and refinancing pressure while preserving financial flexibility. This provides some resilience as the company funds development activities, although the benefit is limited by ongoing losses and the shrinking equity base.
Therapeutic Development PipelineProgressing multiple therapeutic candidates across oncology and women’s health gives the business a defined development focus and potential sources of future value. Partnering aims could also support advancement of selected assets beyond the company’s internal resources.
Revenue ActivityThe existence of revenue indicates the company has generated some commercial or licensing activity rather than remaining entirely pre-revenue. This is a modest positive, but its durability is uncertain because revenue remains very small and declined from 2024.
Bears Say
Minimal And Declining RevenueRevenue remains far too small to support the current cost base and has declined materially year over year. This limits internal funding capacity, leaves the business dependent on future development success, and indicates that commercial scale has not yet been established.
Persistent Cash BurnSustained negative operating and free cash flow shows that operations are not self-funding and that development spending continues to consume cash. Continued burn increases reliance on external funding and may constrain the pace or scope of future pipeline investment.
Shrinking Balance SheetThe contraction in equity and total assets reflects the cumulative effect of losses and cash consumption. A smaller balance sheet reduces financial capacity over time, making the company less able to absorb setbacks or sustain development without additional funding.
ValiRx plc News
EAJF FAQ
What was ValiRx PLC’s price range in the past 12 months?
ValiRx PLC lowest stock price was €0.01 and its highest was €0.12 in the past 12 months.
What is ValiRx PLC’s market cap?
ValiRx PLC’s market cap is €2.68M.
When is ValiRx PLC’s upcoming earnings report date?
ValiRx PLC’s upcoming earnings report date is Jun 09, 2027 which is in 220 days.
How were ValiRx PLC’s earnings last quarter?
ValiRx PLC released its earnings results on Sep 15, 2026. The company reported -€0.001 earnings per share for the quarter.
Is ValiRx PLC overvalued?
According to Wall Street analysts ValiRx PLC’s price is currently Overvalued.
Does ValiRx PLC pay dividends?
ValiRx PLC does not currently pay dividends.
What is ValiRx PLC’s EPS estimate?
ValiRx PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does ValiRx PLC have?
ValiRx PLC has 1,320,301,000 shares outstanding.
What happened to ValiRx PLC’s price movement after its last earnings report?
ValiRx PLC reported an EPS of -€0.001 in its last earnings report. Following the earnings report the stock price went down -20%.
Which hedge fund is a major shareholder of ValiRx PLC?
Currently, no hedge funds are holding shares in DE:EAJF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
ValiRx PLC
ValiRx plc is a UK-based biopharmaceutical company dedicated to pioneering oncology therapeutics and companion diagnostics. Among its primary drug candidates is VAL201, a small molecule that has progressed through Phase I/II trials, aiming to treat prostate cancer and other hormone-dependent solid tumors, including breast and ovarian cancer. Another key candidate, VAL401, a reimagined version of the antipsychotic drug risperidone, has successfully completed Phase II clinical trials for addressing non-small cell lung cancer. The company's pipeline also features VAL301, a peptide currently in pre-clinical development for treating endometriosis in women. Additionally, BC201, a compound combining the peptide ingredient from VAL201/VAL301 with complementary active components, is being developed to alleviate severe symptoms of COVID-19. ValiRx plc was established in 2000 and is headquartered in Hatfield, United Kingdom.
Evgen Pharma
―
ImmuPharma
―
Sareum Holdings
―
Scancell Holdings
―
HemoGenyx Pharmaceuticals Plc
―